risperidone has been researched along with Attention Deficit and Disruptive Behavior Disorders in 72 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Attention Deficit and Disruptive Behavior Disorders: Includes two similar disorders: oppositional defiant disorder and CONDUCT DISORDERS. Symptoms occurring in children with these disorders include: defiance of authority figures, angry outbursts, and other antisocial behaviors.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 9.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone)." | 9.20 | Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. ( Aman, MG; Arnold, LE; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DG; McNamara, N; Molina, BS; Rice, RR; Rundberg-Rivera, EV, 2015) |
| "In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms." | 9.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder." | 9.20 | Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. ( Aman, MG; Arnold, LE; Austin, A; Buchan-Page, KA; Bukstein, OG; Farmer, CA; Findling, RL; Gadow, KD; Kipp, H; Kolko, DJ; McNamara, NK; Michel, C; Molina, BB; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Townsend, LD, 2015) |
| "We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs)." | 9.13 | Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. ( Capone, GT; Goyal, P; Grados, M; Kammann, H; Smith, B, 2008) |
| "The present study aimed to analyse the effect of risperidone on a priori defined core aggression items." | 9.11 | Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. ( Aman, MG; Armenteros, JL; Binder, CE; Hew, H; Kusumakar, V; LeBlanc, JC; Wang, JS, 2005) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 9.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "MEDLINE and EMBASE databases were used to identify controlled studies of risperidone in the treatment of disruptive behavior disorders and pervasive developmental disorders in pediatric patients, acute agitation or aggression in adults, and psychological and behavioral symptoms of dementia in the elderly." | 8.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| "The Panel considered recent studies of the efficacy and tolerability of risperidone and other atypical antipsychotics in adults and children with mental retardation and developmental disabilities." | 8.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 7.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 6.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 5.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "The Treatment of Severe Childhood Aggression (TOSCA) project examined augmentation of stimulant treatment and parent training (PT) with risperidone for severe physical aggression." | 5.24 | Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. ( Aman, MG; Arnold, LE; Barterian, JA; Brown, NV; Bukstein, OG; Farmer, CA; Findling, RL; Kolko, DJ; Molina, BSG; Townsend, L; Williams, C, 2017) |
| "The objective of this study was to evaluate 52-week clinical outcomes of children with co-occurring attention-deficit/hyperactivity disorder (ADHD), disruptive behavior disorder, and serious physical aggression who participated in a prospective, longitudinal study that began with a controlled, 9-week clinical trial comparing the relative efficacy of parent training + stimulant medication + placebo (Basic; n = 84) versus parent training + stimulant + risperidone (Augmented; n = 84)." | 5.22 | Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. ( Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, E; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DJ; Molina, BS; Rice, RR; Schneider, J, 2016) |
| "TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder." | 5.20 | Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. ( Aman, MG; Arnold, LE; Austin, A; Buchan-Page, KA; Bukstein, OG; Farmer, CA; Findling, RL; Gadow, KD; Kipp, H; Kolko, DJ; McNamara, NK; Michel, C; Molina, BB; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Townsend, LD, 2015) |
| "A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone)." | 5.20 | Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. ( Aman, MG; Arnold, LE; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DG; McNamara, N; Molina, BS; Rice, RR; Rundberg-Rivera, EV, 2015) |
| "In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms." | 5.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs)." | 5.13 | Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. ( Capone, GT; Goyal, P; Grados, M; Kammann, H; Smith, B, 2008) |
| "The results of this post hoc analysis of affective symptoms of DBDs using data from a previously published randomized, double-blind clinical comparison of risperidone and placebo in the treatment of children with DBDs and subaverage intelligence suggest that risperidone was effective in treating the factors of explosive irritability; agitated, expansive, grandiose; and depression." | 5.12 | Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. ( Biederman, J; Faraone, SV; Mick, E; Pandina, G; Spencer, T; Wozniak, J, 2006) |
| "The present study aimed to analyse the effect of risperidone on a priori defined core aggression items." | 5.11 | Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. ( Aman, MG; Armenteros, JL; Binder, CE; Hew, H; Kusumakar, V; LeBlanc, JC; Wang, JS, 2005) |
| "The atypical antipsychotic medication risperidone was evaluated using a double-blind, placebo-controlled design in the treatment of destructive behavior in two individuals with autism." | 5.10 | Use of functional analysis methodology in the evaluation of medication effects. ( Crosland, KA; Hellings, JA; Lindauer, SE; Schroeder, SR; Valdovinos, MG; Zarcone, JR; Zarcone, TJ, 2003) |
| "To determine whether risperidone is effective in reducing symptoms of disruptive behaviors (such as aggression, impulsivity, defiance of authority figures, and property destruction) associated with conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified in children with subaverage IQs." | 5.10 | Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. ( Aman, M; Binder, C; Carroll, A; Fisman, S; Snyder, R; Turgay, A, 2002) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 5.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| "MEDLINE and EMBASE databases were used to identify controlled studies of risperidone in the treatment of disruptive behavior disorders and pervasive developmental disorders in pediatric patients, acute agitation or aggression in adults, and psychological and behavioral symptoms of dementia in the elderly." | 4.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| "The Panel considered recent studies of the efficacy and tolerability of risperidone and other atypical antipsychotics in adults and children with mental retardation and developmental disabilities." | 4.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Study 1: Between April 2004 and September 2007, participants were enrolled from outpatient settings in a prospective randomized clinical trial comparing the efficacy of risperidone monotherapy to the combination of risperidone and behavior therapy in targeting disruptive behavior in 4- to 13-year-old children with DSM-IV-TR-based autism spectrum disorder." | 3.81 | Iron homeostasis during risperidone treatment in children and adolescents. ( Aman, M; Arnold, LE; Calarge, CA; Del Castillo, N; McCracken, JT; McDougle, CJ; Scahill, L; Ziegler, EE, 2015) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| " Prolactin levels, hyperprolactinemia, risperidone levels, and 9-hydroxyrisperidone levels were assessed and the participants were genotyped for common CYP2D6 polymorphisms and the Taq1A allele of the dopamine D2 receptor gene." | 3.79 | The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. ( Boot, AM; Buitelaar, JK; Franke, B; Galesloot, TE; Roke, Y; van Harten, PN, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 3.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Risperidone is a promising agent for the treatment of schizophrenia, Tourette's disorder, mood disorders, and disruptive behavior disorders in young populations." | 3.76 | Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. ( Erdogan, A; Karaman, MG; Kurcer, MA; Ozdemir, E; Tufan, AE; Yurteri, N, 2010) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 2.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "Risperidone treatment resulted in no decline in cognitive function among children and adolescents." | 2.74 | Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. ( Cornblatt, B; Pandina, GJ; Zhu, Y, 2009) |
| "Risperidone was generally well tolerated." | 2.73 | Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. ( Haas, M; Karcher, K; Pandina, GJ, 2008) |
| "Risperidone dosage was based on weight (patients <50 kg: 0." | 2.72 | A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. ( Augustyns, I; Buitelaar, J; Eerdekens, M; Reyes, M; Toren, P, 2006) |
| " Safety was assessed using the Extrapyramidal Symptom Rating Scale (ESRS), clinical laboratory tests, electrocardiograms, and the recording of adverse events, vital signs, Tanner score, and changes in body mass index (BMI)." | 2.72 | Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. ( Augustyns, I; Csaba, K; Eerdekens, M; Olah, R; Reyes, M, 2006) |
| "Risperidone-treated patients had clinically and statistically significant reductions in both disruptive behavior and hyperactivity subscale scores, compared to placebo, regardless of concomitant stimulant use." | 2.71 | Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. ( Aman, MG; Binder, C; Turgay, A, 2004) |
| "Risperidone was well tolerated and effective in the long-term treatment of disruptive behavior disorders in children with subaverage intelligence." | 2.71 | Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. ( Croonenberghs, J; De Smedt, G; Fegert, JM; Findling, RL; Van Dongen, S, 2005) |
| " These results were achieved with a mean modal dosage of 1." | 2.71 | Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. ( Eerdekens, M; Gagiano, C; Read, S; Thorpe, L; Van Hove, I, 2005) |
| "Risperidone was associated with rapid, significant improvement on the conduct problem subscale score of the Nisonger Child Behavior Rating Form in patients previously treated with placebo; improvement was maintained during long-term treatment and in patients previously given risperidone." | 2.71 | Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. ( Aman, MG; Derivan, A; Eerdekens, M; Findling, RL; Lyons, B, 2004) |
| "Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint, as well as on the Aberrant Behavior Checklist subscales for irritability, lethargy/social withdrawal, and hyperactivity; the Behavior Problems Inventory aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; and the Clinical Global Impression change score." | 2.70 | Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. ( Aman, MG; De Smedt, G; Derivan, A; Findling, RL; Lyons, B, 2002) |
| "Youth aggression is associated with complex genetic, neurobiological, and environmental risks." | 2.61 | Understanding Chronic Aggression and Its Treatment in Children and Adolescents. ( Magalotti, SR; McVoy, MK; Neudecker, M; Zaraa, SG, 2019) |
| "Risperidone was found to be efficacious in reducing symptoms in children and adolescents with DBD." | 2.49 | Efficacy of risperidone in children with disruptive behavioural disorders. ( Duhig, MJ; Saha, S; Scott, JG, 2013) |
| "Risperidone-treated children had a mean increase in height 1." | 2.42 | Growth and sexual maturation during long-term treatment with risperidone. ( Daneman, D; Dunbar, F; Kusumakar, V; Schulz, M, 2004) |
| "Risperidone was prevalent in younger, male patients with disruptive behavioral disorders; aripiprazole, in patients with tic disorders." | 1.43 | Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison. ( Antoniazzi, S; Auricchio, F; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Gentili, M; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.39) | 18.2507 |
| 2000's | 32 (44.44) | 29.6817 |
| 2010's | 36 (50.00) | 24.3611 |
| 2020's | 3 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Baweja, R | 1 |
| Waxmonsky, JG | 1 |
| Hodgins, GE | 1 |
| Winsor, K | 1 |
| Barnhill, J | 1 |
| Naguy, A | 1 |
| Hashem, MS | 1 |
| AlKhadhar, S | 1 |
| Magalotti, SR | 1 |
| Neudecker, M | 1 |
| Zaraa, SG | 1 |
| McVoy, MK | 1 |
| Cortese, S | 1 |
| Novins, DK | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Masi, G | 1 |
| Manfredi, A | 1 |
| Nieri, G | 1 |
| Muratori, P | 1 |
| Pfanner, C | 1 |
| Milone, A | 1 |
| Barterian, JA | 1 |
| Arnold, LE | 7 |
| Brown, NV | 4 |
| Farmer, CA | 5 |
| Williams, C | 1 |
| Findling, RL | 13 |
| Kolko, DJ | 3 |
| Bukstein, OG | 3 |
| Molina, BSG | 2 |
| Townsend, L | 1 |
| Aman, MG | 12 |
| Fortea, A | 1 |
| Ilzarbe, D | 1 |
| Espinosa, L | 1 |
| Solerdelcoll, M | 1 |
| de Castro, C | 1 |
| Oriolo, G | 1 |
| Sugranyes, G | 1 |
| Baeza, I | 1 |
| Shafiq, S | 1 |
| Pringsheim, T | 2 |
| Joseph, HM | 1 |
| Farmer, C | 1 |
| Kipp, H | 2 |
| Kolko, D | 1 |
| Aman, M | 4 |
| McGinley, J | 1 |
| Gadow, KD | 5 |
| Weiss, MD | 1 |
| Margari, L | 1 |
| Matera, E | 1 |
| Craig, F | 1 |
| Petruzzelli, MG | 1 |
| Palmieri, VO | 1 |
| Pastore, A | 1 |
| Margari, F | 1 |
| Roke, Y | 2 |
| van Harten, PN | 2 |
| Franke, B | 1 |
| Galesloot, TE | 1 |
| Boot, AM | 2 |
| Buitelaar, JK | 3 |
| Baribeau, DA | 1 |
| Anagnostou, E | 1 |
| Elbe, D | 1 |
| Barr, AM | 1 |
| Honer, WG | 1 |
| Procyshyn, RM | 1 |
| Kolko, DG | 1 |
| Molina, BS | 3 |
| Buchan-Page, KA | 3 |
| Rice, RR | 3 |
| Bangalore, SS | 1 |
| Bukstein, O | 2 |
| Rundberg-Rivera, EV | 3 |
| McNamara, N | 1 |
| Li, X | 1 |
| Bangalore, S | 1 |
| Buchan-Page, K | 1 |
| Hurt, EA | 1 |
| Rice, R | 1 |
| McNamara, NK | 3 |
| Townsend, LD | 1 |
| Schneider, J | 2 |
| Molina, BB | 1 |
| Michel, C | 1 |
| Austin, A | 1 |
| Ince, E | 1 |
| Algedik, P | 1 |
| Demirdogen, ES | 1 |
| Emul, M | 1 |
| Demir, T | 1 |
| Calarge, CA | 2 |
| Burns, TL | 1 |
| Schlechte, JA | 1 |
| Zemel, BS | 1 |
| Ziegler, EE | 1 |
| Del Castillo, N | 1 |
| McDougle, CJ | 1 |
| Scahill, L | 1 |
| McCracken, JT | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Daneman, D | 2 |
| Butter, E | 1 |
| Pozzi, M | 1 |
| Pisano, S | 1 |
| Bertella, S | 1 |
| Capuano, A | 1 |
| Rizzo, R | 1 |
| Antoniazzi, S | 1 |
| Auricchio, F | 1 |
| Carnovale, C | 1 |
| Cattaneo, D | 1 |
| Ferrajolo, C | 1 |
| Gentili, M | 1 |
| Guastella, G | 1 |
| Mani, E | 1 |
| Rafaniello, C | 1 |
| Riccio, MP | 1 |
| Scuderi, MG | 1 |
| Sperandeo, S | 1 |
| Sportiello, L | 1 |
| Villa, L | 1 |
| Radice, S | 1 |
| Clementi, E | 1 |
| Rossi, F | 1 |
| Pascotto, A | 1 |
| Bernardini, R | 1 |
| Molteni, M | 1 |
| Bravaccio, C | 1 |
| Jahangard, L | 1 |
| Akbarian, S | 1 |
| Haghighi, M | 1 |
| Ahmadpanah, M | 1 |
| Keshavarzi, A | 1 |
| Bajoghli, H | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Chang, KD | 1 |
| Haas, M | 1 |
| Karcher, K | 1 |
| Pandina, GJ | 4 |
| Bandou, N | 1 |
| Koike, K | 1 |
| Matuura, H | 1 |
| Zhu, Y | 1 |
| Cornblatt, B | 1 |
| Rothermel, B | 1 |
| Poustka, L | 1 |
| Banaschewski, T | 1 |
| Becker, K | 1 |
| Erdogan, A | 1 |
| Karaman, MG | 1 |
| Ozdemir, E | 1 |
| Yurteri, N | 1 |
| Tufan, AE | 1 |
| Kurcer, MA | 1 |
| McKinney, C | 1 |
| Renk, K | 1 |
| Martínez-Ortega, JM | 1 |
| Diaz-Atienza, F | 1 |
| Gutiérrez-Rojas, L | 1 |
| Jurado, D | 1 |
| Gurpegui, M | 1 |
| Duhig, MJ | 1 |
| Saha, S | 1 |
| Scott, JG | 1 |
| West, AE | 1 |
| Weinstein, SM | 1 |
| Celio, CI | 1 |
| Henry, D | 1 |
| Pavuluri, MN | 1 |
| Stern, AP | 1 |
| Trieu, ML | 1 |
| Gorman, D | 1 |
| Tenback, D | 1 |
| Lohr, WD | 1 |
| Honaker, J | 1 |
| De Smedt, G | 2 |
| Derivan, A | 2 |
| Lyons, B | 2 |
| Snyder, R | 1 |
| Turgay, A | 2 |
| Binder, C | 3 |
| Fisman, S | 1 |
| Carroll, A | 1 |
| Martin, A | 1 |
| L'Ecuyer, S | 1 |
| Crosland, KA | 1 |
| Zarcone, JR | 1 |
| Lindauer, SE | 1 |
| Valdovinos, MG | 1 |
| Zarcone, TJ | 1 |
| Hellings, JA | 1 |
| Schroeder, SR | 1 |
| Eerdekens, M | 4 |
| Dunbar, F | 1 |
| Kusumakar, V | 2 |
| Schulz, M | 1 |
| Gharabawi, GM | 1 |
| Croonenberghs, J | 1 |
| Fegert, JM | 1 |
| Van Dongen, S | 1 |
| Gagiano, C | 1 |
| Read, S | 1 |
| Thorpe, L | 1 |
| Van Hove, I | 1 |
| Buitelaar, J | 3 |
| Smedt, GD | 1 |
| Wapenaar, R | 1 |
| Lauwers, K | 1 |
| De Hert, M | 1 |
| LeBlanc, JC | 1 |
| Binder, CE | 1 |
| Armenteros, JL | 1 |
| Wang, JS | 1 |
| Hew, H | 1 |
| Keenan, K | 1 |
| De Deyn, PP | 1 |
| Reyes, M | 2 |
| Toren, P | 1 |
| Augustyns, I | 2 |
| Olah, R | 1 |
| Csaba, K | 1 |
| Biederman, J | 1 |
| Mick, E | 1 |
| Faraone, SV | 1 |
| Wozniak, J | 1 |
| Spencer, T | 1 |
| Pandina, G | 1 |
| Shatkin, JP | 1 |
| Ipser, J | 1 |
| Stein, DJ | 1 |
| Günther, T | 1 |
| Herpertz-Dahlmann, B | 1 |
| Jolles, J | 1 |
| Konrad, K | 1 |
| Bilder, R | 1 |
| Harvey, PD | 1 |
| Keefe, RS | 1 |
| Gharabawi, G | 1 |
| Sabuncuoglu, O | 1 |
| Winsberg, B | 1 |
| Usubiaga, H | 1 |
| Cooper, T | 1 |
| Capone, GT | 1 |
| Goyal, P | 1 |
| Grados, M | 1 |
| Smith, B | 1 |
| Kammann, H | 1 |
| Roberts, MD | 1 |
| van der Gaag, RJ | 1 |
| Cohen-Kettenis, P | 1 |
| Melman, CT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stimulant and Risperidone in Children With Severe Physical Aggression[NCT00796302] | Phase 4 | 168 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00266552] | Phase 3 | 118 participants (Actual) | Interventional | Completed | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00250354] | Phase 3 | 110 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antisocial Behavior Scale (ABS) is a 28-item scale that contains 10 Proactive Aggression items and six Reactive Aggression items. Each item is rated on a 3-point scale, ranging from 1 (Never) to 3 (Very often). Thus, scores on the Reactive Aggression subscale can range from 6 through 18; with higher scores indicating more reactive aggression. (NCT00796302)
Timeframe: Measured at baseline and Week 9
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 15.5 | 11.0 |
| Basic (Stimulant + PMT + Placebo) | 15.9 | 12.3 |
"Using this clinician rating scale the patient's improvement is scored on a 7-point scale which ranges from very much improved (1), through no change (4), to very much worse (7). This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Improvement scores are reported below." (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | ||
|---|---|---|---|
| Much or very much improved at endpoint | Minimally improved at endpoint | Unchanged or worse at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 63 | 11 | 6 |
| Basic (Stimulant + PMT + Placebo) | 58 | 22 | 3 |
Using this clinician rating scale the severity of the illness is scored from 1= normal to 7= extremely ill. This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Severity of Illness scores are reported below. (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | |
|---|---|---|
| Normal/Borderline/Mildly ill at endpoint | Moderately/Markedly/Severely ill at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 56 | 22 |
| Basic (Stimulant + PMT + Placebo) | 49 | 34 |
"Parent ratings of aggression and hostility on the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ) D-Total Score. The NCBRF provides 1 prosocial subscale (Positive/Social) and 6 problem behavior subscales (Conduct Problem, Oppositional Behavior, Hyperactive, Inattentive, Overly Sensitive, and Withdrawn/Dysphoric). The NCBRF has excellent internal consistency, distinguishes between controls and subjects with DBDs. Conduct Problem and Oppositional Behavior subscales map closely to DSM-IV-TR symptoms of CD and ODD; they were scored together to form a variable called the D-Total.~For the NCBRF D-Total, higher scores reflect worse behavior. Each subscale is scored by taking the rating (0 [did not occur or was not a problem] to 3 [occurred a lot or was a very severe problem]) for all component items. The D-Total score was computed by adding the 6 scores from the Oppositional subscale and the 10 items from the Conduct Problem subscale. Thus D-Total scores could range from 0-69." (NCT00796302)
Timeframe: Measured at baseline and Weeks 3, 4, 5, 6, 7, 8, 9
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 42.1 | 25.9 | 17.1 | 12.1 | 13.8 | 13.0 | 11.7 | 10.7 |
| Basic (Stimulant + PMT + Placebo) | 43.5 | 24.9 | 22.4 | 20.1 | 20.7 | 16.8 | 17.8 | 17.8 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
20 reviews available for risperidone and Attention Deficit and Disruptive Behavior Disorders
| Article | Year |
|---|---|
Updates in Pharmacologic Strategies for Emotional Dysregulation in Attention Deficit Hyperactivity Disorder.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disor | 2022 |
Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Child; Conduct Disorder; Humans; In | 2022 |
Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2019 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
Using antipsychotics for behavioral problems in children.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Autism Spec | 2018 |
An update on medication management of behavioral disorders in autism.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Atomoxetine | 2014 |
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2011 |
Efficacy of risperidone in children with disruptive behavioural disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Humans | 2013 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2012 |
Atypical antipsychotics for the treatment of disruptive behavior.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2013 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2004 |
Growth and sexual maturation during long-term treatment with risperidone.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2004 |
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia Dise | 2004 |
Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQ.
Topics: Analysis of Variance; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chi | 2005 |
Risperidone in the management of agitation and aggression associated with psychiatric disorders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Humans; Menta | 2006 |
Risperidone in the management of disruptive behavior disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2006 |
Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Child; Humans; Lithium Compounds; P | 2007 |
25 trials available for risperidone and Attention Deficit and Disruptive Behavior Disorders
| Article | Year |
|---|---|
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2017 |
Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Central Nervo | 2017 |
Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2019 |
Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2015 |
Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Topics: Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2015 |
Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Central Nervo | 2016 |
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical t
Topics: Adjuvants, Pharmaceutic; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Diso | 2017 |
Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia | 2008 |
Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2009 |
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2011 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
Topics: Analysis of Variance; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chi | 2002 |
Use of functional analysis methodology in the evaluation of medication effects.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autist | 2003 |
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, Preschool; | 2004 |
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2004 |
Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2005 |
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.
Topics: Adolescent; Adult; Attention Deficit and Disruptive Behavior Disorders; Disorders of Excessive Somno | 2005 |
Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2005 |
A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2006 |
Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Body Mass Index; Child; Diagnostic | 2006 |
Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.
Topics: Affective Symptoms; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Depre | 2006 |
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripipraz | 2007 |
Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Central Nervous | 2008 |
A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; B | 2001 |
27 other studies available for risperidone and Attention Deficit and Disruptive Behavior Disorders
| Article | Year |
|---|---|
Atypical antipsychotics for Attention-Deficit/Hyperactivity disorder- science, art, or fad?
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2019 |
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2021 |
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2018 |
Review: Limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Dibenzothiazepines; Human | 2013 |
Tolerability and safety profile of risperidone in a sample of children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Composit | 2013 |
The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Topics: Adolescent; Alleles; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chil | 2013 |
Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2014 |
The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2015 |
Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Bone Density; Child; Humans; Longit | 2015 |
Iron homeostasis during risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autism Spectr | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Prolactin Levels During Long-Term Risperidone Treatment in Children and Adolescents: a reanalysis of data.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Data I | 2016 |
Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2016 |
Predictive familial risk factors and pharmacological responses in ADHD with comorbid disruptive behavior disorders.
Topics: Adolescent; Age Distribution; Analysis of Variance; Attention Deficit and Disruptive Behavior Disord | 2010 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Weight; | 2010 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disrupti | 2011 |
A case of antipsychotic-induced hyperglycemia in a child with insulin dependent diabetes mellitus.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2012 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; | 2012 |
Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Attention Deficit and Disruptive B | 2002 |
Glucose abnormalities in a non-psychotic patient treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Diabetes Mell | 2005 |
Antipsychotics in disruptive behavior disorders and ADHD.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2005 |
Elucidating the role of risperidone in the treatment of disruptive behavior disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Humans | 2006 |
The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention; Attention Deficit and Disruptive Behavior D | 2006 |
Risperidone and cognitive function in children with disruptive behavior disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2007 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |
Risperdal and parkinsonian tremor.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 1999 |